海峽創新(300300.SZ):間接持有京東數科的股份比例及賬面價值較小
格隆匯 5 月 6日丨海峽創新(300300.SZ)發佈股票異常波動的公吿,近期,公司關注到有投資者在部分股票交流平台將公司稱為“京東金融概念股”。目前,公司全資子公司浙江漢鼎宇佑資本管理有限公司持有宿遷漢鼎錦繡投資管理合夥(有限合夥)(“漢鼎錦繡投資”)3.57%股權,漢鼎錦繡投資持有京東數字科技控股股份有限公司(“京東數科”)0.34%股份。公司間接持有京東數科的股份比例及賬面價值較小,且未參與京東數科的經營管理,預計不會對公司2021年度的業績產生重大影響。
除此以外公司未發現近期公共傳媒報道了與公司相關且市場關注度較高的信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.